Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

NCT02001623 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT02001623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02001623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Lead sponsor
Seagen Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2013
Completion date
May 2, 2019
Enrollment
195 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cervix cancer, endometrium cancer, esophagus cancer, lung cancer(nsclc), ovary cancer, prostate cancer (crpc), squamous cell carcinoma of the head and neck (scchn)